Lennox-Gastaut syndrome
Neurology · 2020–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| cannabidiol Seizures associated with Lennox-Gastaut syndrome (LGS). The submission sought amendments to PBS restrictions, including changes to the authority level from… | Jul 2025 | Recommended with restriction | input received Epilepsy Action Australia · Epilepsy Foundation |
| cannabidiol Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome aged 2 years and older who have not achieved adequate seizure control with at least… | Jul 2022 | Not recommended | none received |
| cannabidiol Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome aged 2 years and older who have not achieved adequate seizure control with at least… | Jul 2022 | Recommended with restriction | none received |
| cannabidiol Seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older with inadequate control on at least two other anti-epileptic drugs,… | Mar 2022 | Not recommended | 9 individuals Epilepsy Society of Australia · Epilepsy Nurse Specialist Interest Group |
| cannabidiol Adjunctive therapy to treat seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older. | Jul 2020 | Deferred | input received Epilepsy Society of Australia · Epilepsy Society · Epilepsy Foundation |
Who spoke
Epilepsy Foundation · Epilepsy Society of Australia · Epilepsy Action Australia · Epilepsy Society · Epilepsy Nurse Specialist Interest Group
What the PBS pays
$17M in government benefit over 2024–25, across 6,142 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| cannabidiol | $16.6M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| fenfluramineFenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over | TA1050 | recommended restricted | 2025-03 |
| cannabidiolCannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome | TA615 | recommended restricted | 2019-12 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.